Royal Bank Of Canada Galecto, Inc. Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.47 - $0.76 $55 - $89	118 Added 157.33%	193 $0
Q1 2024 Nov 05, 2024	SELL	$0.6 - $0.89 $70 - $105	-118 Reduced 61.14%	75 $0
Q1 2024 May 15, 2024	SELL	$0.6 - $0.89 $19 - $29	-33 Reduced 30.56%	75 $0
Q4 2023 Feb 14, 2024	BUY	$0.52 - $0.78 $56 - $84	108 New	108 $0

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $119M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.